• Oncoceutics has been selected to present on the Discovery Track at the 14th Annual Bio Investor Forum, which will take place on October 20-21, 2015, in San Francisco. Oncoceutics is delighted to have been chosen to take part in the BIO Investor Forum, which is designed to “explore investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth ‘watch list’ in 2016.”  Lee Schalop, the company’s Chief Business Officer, will present an overview of the Company’s business strategy and on its lead compound ONC201, which is currently in clinical trials at leading cancer centers around the country.